Targeting Aggregated Peptides for Traumatic Brain Injury Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for traumatic brain injury lack effective methods to reduce aggregated forms of peptides such as amyloid-beta, alpha-synuclein, and tau, which contribute to severe damage and complications following acute brain injuries, due to incomplete understanding of pathogenesis and limited specificity of existing therapeutic agents.

Innovation Solution

Administration of agents capable of reducing aggregated forms of peptides, including antibodies with high affinity for protofibrils, to target and eliminate or reduce toxic peptide aggregates in the brain, thereby alleviating or treating traumatic brain injury and predicting potential complications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing therapeutic agents are used to treat traumatic brain injury, then general neuroprotection may be achieved, but they lack specificity to target aggregated peptide forms

Engineering Contradiction:

Improvespecificity of therapeutic agentVSAvoidbroad applicability to different peptide aggregates

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent employs antibodies with distinct binding specificities tailored to different aggregate states of Aβ peptides. Monoclonal antibody 4G8 specifically targets monomeric Aβ, while 6E10 targets oligomeric forms, and 158 targets fibrillar aggregates. This localized specificity allows each antibody to address particular pathological forms without cross-reactivity, resolving the contradiction between specificity and broad applicability.

Inventive Principle:

Principle #3Local quality

2Adaptability or versatility

If broad-spectrum antibodies targeting various Aβ forms are used, then multiple aggregate types may be addressed, but the therapeutic effect is reduced due to lower specificity

Engineering Contradiction:

Improveability to target multiple Aβ formsVSAvoidtherapeutic effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The therapeutic approach is segmented into multiple specialized antibodies, each optimized for a specific aggregate form. Rather than using a single broad-spectrum antibody with reduced efficacy, the patent divides the therapeutic function across several monoclonal antibodies (4G8 for monomers, 6E10 for oligomers, 158 for fibrils), allowing each to exert maximum therapeutic effect on its target aggregate type.

Inventive Principle:

Principle #1Segmentation

3Ease of operation

If non-specific therapeutic agents are administered, then treatment can be applied broadly, but they fail to effectively reduce toxic peptide aggregates

Engineering Contradiction:

Improvesimplicity of treatment administrationVSAvoidability to reduce peptide aggregates

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent introduces highly specific monoclonal antibodies as intermediary agents that bridge the gap between simple administration and complex pathological targets. These antibodies serve as precise mediators that recognize and bind to specific epitopes on Aβ aggregates through their variable regions, enabling selective neutralization and clearance of toxic forms while maintaining straightforward intravenous or intracerebroventricular administration protocols.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Significant reduction of peptide aggregates leads to improved neurological outcomes, such as enhanced arousal, reduced risk of prolonged unconsciousness, and improved cognitive function, with potential preventive effects against neurodegenerative diseases like Alzheimer's.

Implementation Method 1

administration of agents capable of reducing aggregated forms of peptides, including antibodies with high affinity for protofibrils, to target and eliminate or reduce toxic peptide aggregates in the brain

Methodology Applied

Scientific EffectAntibody binding:

Data Source

PatentUS11327080B2Method for treatment of traumatic brain injury targeting aggregated peptides

Publication Date: 2022.05.10 BIOARCTIC AB

AI summary

A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain. An agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain is suitable for use in preventing, alleviating or treating traumatic brain injury. A method for predication of the risk of an individual for complications after a traumatic brain injury comprises detecting one or more aggregated forms of one or more peptides prone to aggregate as a result of a traumatic brain injury event, in the brain of the individual, wherein an increased level of such aggregates in the brain indicates an increased risk for complications.